Test Price
2,800 AED✅ Home Collection Available
SOX11 Gene Mental Retardation, Autosomal Dominant Type 27 Genetic Test in UAE | 2800 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
Executive Summary: This advanced genetic test analyzes the SOX11 gene for pathogenic variants associated with autosomal dominant intellectual disability type 27 (MRD27). With 99.9% diagnostic sensitivity, it is performed in our ISO 9001:2015 accredited laboratory (Cert: INT/EGQ/2509DA/3139). VIP mobile phlebotomy and temperature-controlled cold-chain home collection are available daily from 8 AM to 11 PM. A telephonic post-test clinical guidance consultation with a DHA-licensed expert is provided.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: Hospital‑Grade, ISO‑Certified Cold‑Chain Home Collection by VIP Mobile Phlebotomists.
- Clinical Guidance: Telephonic Post‑Test Clinical Guidance with a DHA‑Licensed Expert for Result Interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The SOX11 NGS test identifies pathogenic variants in the SOX11 gene responsible for autosomal dominant intellectual disability type 27 (MRD27). This test is indispensable for paediatric neurologists, clinical geneticists, and families seeking a definitive molecular diagnosis for unexplained developmental delay. It delivers full gene coverage, including deep intronic and exonic regions, ensuring high diagnostic yield.
| Feature | Our Test (NGS) | Closest Alternative (Sanger) |
|---|---|---|
| Precision | Full gene coverage, deep intronic/exonic | Limited to selected exons |
| Method | Next Generation Sequencing (NGS) | Capillary electrophoresis |
| Speed | 3 to 4 Weeks | 6 to 8 Weeks |
Physician Insight & Safety Protocols
“The SOX11 gene test is a powerful tool for diagnosing MRD27, but results must be interpreted in the context of a comprehensive clinical evaluation. Pre‑ and post‑test genetic counselling is essential to help families understand the implications for the child and family. A negative result does not exclude other genetic causes.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⛔ Critical Advisory
Never alter or discontinue prescribed treatments based solely on this test result. This diagnostic tool provides molecular insight; it does not replace the clinical judgment of a treating physician. Continue all medications until advised otherwise by your doctor.
Exclusion Criteria & ER Red Flags
- Active severe infection or acute metabolic crisis at the time of sample collection – reschedule until resolved.
- Recent blood transfusion (within 4 weeks) may interfere with germline DNA analysis – defer testing.
- ER Red Flags: If the patient experiences sudden loss of consciousness, intractable seizures, or acute encephalopathy, seek immediate medical assistance and do not rely solely on a pending genetic result.
Patient FAQ & Clinical Guidance
1. What exactly does the SOX11 NGS test detect?
The test analyzes the entire SOX11 gene for single nucleotide variants, small insertions/deletions, and copy number changes linked to autosomal dominant intellectual disability type 27. It provides a definitive molecular diagnosis for unexplained developmental delay.
2. How should I prepare my child for the blood draw?
Collecting a sample requires only a small blood volume; your child should be well‑hydrated and calm. Our paediatric phlebotomist will use a gentle, age‑appropriate technique, and no fasting is needed. Home collection is available with cold‑chain transport.
3. When will I receive the results, and who will explain them?
Results are delivered within 3 to 4 weeks through a secure portal, accompanied by a comprehensive clinical report. A DHA‑licensed genetics expert will provide a complimentary tele‑consultation to guide the next steps and discuss implications for the family.
UAE Regulatory & Data Privacy Adherence
All procedures strictly comply with UAE federal regulations:
- Data Protection: Adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – all patient information is encrypted and processed within UAE‑licensed facilities.
- Health ICT: Compliant with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical Safety & Consent: Governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability, ensuring informed consent and patient safety during sample collection.
Clinical & Logistical Metadata
| Test Name | SOX11 Gene Mental Retardation, Autosomal Dominant Type 27 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card |
| Methodology Used | Next Generation Sequencing (NGS) |
| ICD-10-CM Code | Q87.89 |
| LOINC Code | 92822-6 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians